Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Feb 11;17(2):e0263597. doi: 10.1371/journal.pone.0263597

Test-trace-isolate-quarantine (TTIQ) intervention strategies after symptomatic COVID-19 case identification

Peter Ashcroft 1,*, Sonja Lehtinen 1, Sebastian Bonhoeffer 1,*
Editor: Seth Blumberg2
PMCID: PMC8836351  PMID: 35148359

Abstract

The test-trace-isolate-quarantine (TTIQ) strategy, where confirmed-positive pathogen carriers are isolated from the community and their recent close contacts are identified and pre-emptively quarantined, is used to break chains of transmission during a disease outbreak. The protocol is frequently followed after an individual presents with disease symptoms, at which point they will be tested for the pathogen. This TTIQ strategy, along with hygiene and social distancing measures, make up the non-pharmaceutical interventions that are utilised to suppress the ongoing COVID-19 pandemic. Here we develop a tractable mathematical model of disease transmission and the TTIQ intervention to quantify how the probability of detecting and isolating a case following symptom onset, the fraction of contacts that are identified and quarantined, and the delays inherent to these processes impact epidemic growth. In the model, the timing of disease transmission and symptom onset, as well as the frequency of asymptomatic cases, is based on empirical distributions of SARS-CoV-2 infection dynamics, while the isolation of confirmed cases and quarantine of their contacts is implemented by truncating their respective infectious periods. We find that a successful TTIQ strategy requires intensive testing: the majority of transmission is prevented by isolating symptomatic individuals and doing so in a short amount of time. Despite the lesser impact, additional contact tracing and quarantine increases the parameter space in which an epidemic is controllable and is necessary to control epidemics with a high reproductive number. TTIQ could remain an important intervention for the foreseeable future of the COVID-19 pandemic due to slow vaccine rollout and highly-transmissible variants with the potential for vaccine escape. Our results can be used to assess how TTIQ can be improved and optimised, and the methodology represents an improvement over previous quantification methods that is applicable to future epidemic scenarios.

Introduction

Individuals who are confirmed as infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are isolated from the community to prevent further transmission. Individuals who have been in recent close contact with an infected individual have an increased risk of being infected themselves. By identifying the potentially-infected contacts through contact tracing and eventually quarantining them, transmission chains can be broken. Thus contact tracing is an essential public health tool for controlling epidemics [1]. The strategy of testing to identify infected cases, isolating them to prevent further transmission, and tracing & quarantining their recent close contacts is known as test-trace-isolate-quarantine (TTIQ) [2]. This strategy is a key non-pharmaceutical intervention which is used globally to control the ongoing COVID-19 pandemic [3].

Testing typically occurs once an individual develops symptoms indicative of coronavirus disease 2019 (COVID-19). As presymptomatic transmission makes up approximately 40% of total onward transmission from eventually-symptomatic infecteds [46], it would be possible for the number of secondary infections to be more than halved if infected individuals were isolated from the community at the time of symptom onset. However, as testing follows from symptoms in this scenario, the testing & isolating strategy without subsequent contact tracing & quarantine is unlikely to capture persistently-asymptomatic infections which make up around 20% of all infecteds [7], and thus isolating 100% of infecteds at symptom onset would not be possible.

Contact tracing & quarantine have the potential to be effective interventions against the spread of COVID-19 because of the high frequency of presymptomatic and asymptomatic transmission from recently-infected individuals [8]. Potentially-infected contacts can be identified and quarantined before they would be isolated as a result of developing symptoms and/or receiving a positive test result, such that their onward transmission is reduced. This is exemplified during super-spreader events [911] where large numbers of potentially-infected contacts can be quarantined to prevent widespread community transmission. Tracing & quarantine do not depend on symptom development, hence this strategy is capable of reducing onward transmission even from asymptomatically-infected individuals.

TTIQ strategies are not perfect: each stage in the process is subject to delays and uncertainties and it would be impossible to prevent all transmission through TTIQ alone [3, 1216]. Here we will systematically assess how the probability of identifying and isolating a symptomatic case, the fraction of contacts identified and quarantined, and the delays that are inherent to these processes impact disease transmission under TTIQ interventions. From this quantification we can determine how TTIQ can be improved and optimised. For example, in the presence of widespread community transmission when contact tracers may be overwhelmed by the volume of cases, it is important to optimise the available resources (e.g. the person hours of the contact tracers) to minimise onward transmission.

Previous studies employing different approaches have begun to address these questions. Ferretti et al. [12] concluded that minimal delay between index case identification and quarantine of secondary contacts (as achieved with widespread digital contact tracing) is necessary to reduce the effective reproduction number below one and to bring an outbreak under control. Kretzschmar et al. [13] also predominantly focussed on digital contact tracing based on mobile applications, confirming the conclusions of Ferretti et al. [12] that minimising delays is the key to a successful TTIQ intervention. Through simulations based on real-world contact networks, Kucharski et al. [3] concluded that > 75% of contacts have to be quarantined (through manual contact tracing or digital app-based tracing) to reduce the effective reproduction number below one. Finally, Grantz et al. [17] employed a discrete-time Markov chain model of transmission, isolation, and contact tracing to conclude that effective TTIQ interventions need to be strong in the “test” component, as case detection underlies all other TTIQ components.

In this paper we build on our previous modelling work in which we have quantified the impact of quarantine duration and highlighted the optimal use of test-and-release strategies [16]. With this mathematical framework, which uses the empirically-observed distributions of transmission timing from Ferretti et al. [6] to determine when infections occur, we systematically quantify the effective reproduction number in the presence of TTIQ.

Although a global roll-out of vaccines against SARS-CoV-2 is under way, non-pharmaceutical interventions are likely to remain crucial to epidemic control for the foreseeable future [18, 19]. Furthermore, we are still at risk from new variants which are highly-transmissible and/or less impeded by current vaccines and acquired immunity. Our framework is flexible enough to quantify the limitations of TTIQ in these scenarios, as well as provide insight about how these interventions can be optimised.

Materials and methods

Transmission model

Our transmission model is based on a branching process that starts with a single individual who is infected with SARS-CoV-2. The branching process model assumes discrete generations of transmission and an infinite population size, such that the expected number of secondary infections per infected is the same across generations. We therefore do not explicitly include the depletion of susceptibles due to death or acquired immunity during epidemic spread and/or vaccination campaigns. The initial infected individual could be persistently asymptomatic (which make up a fraction a of infections), otherwise they are classed as symptomatic (1 − a). To be clear, presymptomatic individuals who will go on to develop symptoms are included in the symptomatic fraction. Buitrago-Garcia et al. [7] have estimated a ≈ 20% based on a meta-analysis of 79 studies.

The timing of onward infections in the model is determined by empirically-observed distributions of transmission dynamics from Ferretti et al. [6]. These distributions are: the generation time distribution (describing the time interval between the infection of an index case and secondary case); the infectivity profile (describing the time interval between the onset of symptoms in the index case and infection of the secondary case); and the incubation period distribution (describing the time between the infection of an individual and the onset of their symptoms). These distributions (shown in Fig I in S1 Appendix) are based on large sets of transmission pairs and minimal assumptions about the relationship between infectiousness and symptoms, which would otherwise push the variance of the resulting generation time distribution towards its upper or lower extremes [20]. The fraction of transmission that occurs before symptom onset in symptomatically-infected individuals is defined by the cumulative infectivity profile (or generation time) up to the time of symptom onset. The infectivity profile and incubation periods are undefined (and unnecessary) for asymptomatic cases, and in the model we make the simplifying assumption that the generation time distribution is the same between asymptomatic and symptomatic cases.

Using the branching process model we calculate the number of infected individuals in the second generation (secondary infections) and in the third generation (tertiary infections) after the introduction of the first infected individual. We also keep track of the time at which the transmission events occur. In our analysis we do not simulate the branching process explicitly, but instead use a statistical description of the dynamics.

The expected number of secondary infections per infected depends on the transmissibility of the virus (e.g. as captured by the basic reproductive number R0), as well as the current level of interventions in place to mitigate the spread of the virus. As we are interested in quantifying the effects of TTIQ strategies, we introduce the parameter R which represents the effective reproductive number of the virus in the presence of interventions such as mask-wearing, social distancing, school closures etc., but in the absence of isolation and quarantine. We refer to this R parameter as “the baseline R-value in the absence of TTIQ”, and we have RR0 due to the presence of the non-TTIQ preventative measures. Furthermore, the baseline reproductive number R should be greater than or equal to the currently observed effective reproductive number, which includes the impact of in-place TTIQ measures. In the absence of TTIQ interventions, we would expect R infections in the second generation, and R2 infections in the third generation. This R-value will depend on the strain of SARS-CoV-2 that is considered, for example new variants of concern such as Alpha (B.1.1.7) and Delta (B.1.617.2) are significantly more transmissible than pre-existing variants [2123]. The R-value will also be proportional to the size of the susceptible pool—which can be depleted due to death or acquired immunity—such that epidemic spread and vaccination campaigns will result in a smaller baseline R-value.

Furthermore, this R-value represents the average effective reproductive number across asymptomatic and symptomatic infections, i.e. R = aRa + (1 − a)Rs, where Ra and Rs are the expected number of individuals who are directly infected by an asymptomatic or symptomatic individual in the absence of TTIQ, respectively. From the literature, we would expect that RaRs [7]. We can further define the parameter α = aRa/R as the fraction of all transmission that originates from asymptomatically-infected individuals in the absence of TTIQ. This fraction has the property that if asymptomatic and symptomatic individuals are equally transmissive (Ra = Rs), then α is just the fraction of asymptomatic individuals (α = a). If asymptomatic individuals are less infectious (Ra < Rs), then α < a. Therefore the fraction of transmission from asymptomatic individuals in the absence of TTIQ satisfies 0 ≤ αa.

Testing & isolating

Individuals who develop symptoms that are indicative of COVID-19 can be tested and subsequently isolated from the population. Testing & isolating acts to reduce the number of secondary infections per index case by shortening the duration in which the index case can infect susceptible individuals, i.e. isolation truncates the distribution of infection times (Fig 1A). We assume that isolation happens after a fixed delay of Δ1 days after symptom onset, and that only a fraction f of symptomatic individuals are isolated. This incomplete coverage can be attributed to symptom misdiagnosis, a failure or unwillingness to get tested if symptomatic, a false-negative test result, or non-adherence to the isolation protocol. The fraction isolated f can also be reduced by false-negative results based on potentially less-sensitive self-administered tests, which could prevent infected individuals from seeking confirmatory point-of-care tests. For those individuals who are isolated, we assume that they cannot infect further for the remaining duration of their infectious period. This assumption of perfect adherence to isolation once tested positive will lead to an overestimation of TTIQ effectiveness. Any lack of adherence to isolation could be accounted for in the model by reducing f, as long as this lack of adherence also means that their contacts are not traced. In the model, asymptomatic individuals are not subject to symptomatic testing and isolation. These asymptomatic individuals could be tested during surveillance (mass-testing or surge testing), and isolation would follow as above if a positive test result is obtained. However, in the scenario we are considering, only symptomatically-infected individuals will be tested and isolated.

Fig 1. Quantifying the impact of TTIQ interventions using a mathematical model.

Fig 1

A: Under testing & isolation, index cases are identified and isolated from the population after a delay Δ1 after they develop symptoms (at time tS1). This curtails their duration of infectiousness and reduces the number of secondary infections. This isolation occurs in a fraction f of symptomatic individuals. B: Under additional contact tracing & quarantine, the contacts of an index case can be identified and quarantined after an additional delay Δ2. This reduces the onward transmission from these secondary contacts. Only contacts that occur during the contact tracing window can be identified. This window extends from τ days before the index case developed symptoms (i.e. tS1-τ) to the time at which the index case was isolated (i.e. tS1+Δ1). A fraction g of the contacts who were infected within the contact tracing window are quarantined. The remaining individuals are not quarantined, but could be isolated if they are later detected as an index case. The distributions shown here are schematic representations of the infectivity profile and/or generation time interval, which are quantitatively displayed in Fig I in S1 Appendix. These distributions reflect an individual’s infectiousness as a function of time.

The infected individuals who are not isolated will infect Ra or Rs secondary contacts, depending on whether they are classified as asymptomatic or symptomatic. Isolated symptomatic cases will infect P1) × Rs secondary contacts, where 0 ≤ P1) ≤ 1 is the cumulative fraction of the infection time distribution that lies before the isolation time Δ1 (see Fig 1A). Averaging across these scenarios gives the expected number of secondary infections per infected case. We can repeat this analysis for each of the secondary infections to calculate the number tertiary infections under testing & isolation. See S1 Appendix for the full calculation.

Contact tracing & quarantine

When a symptomatic index case is identified by testing, they can be interviewed by contact tracers to determine whom they have potentially infected, with the aim of quarantining these exposed individuals. The contact tracers focus on a specific time window of infection to identify the contacts with highest risk of being infected. In our model this window extends to τ days before symptom onset in the index case. It is unlikely that every contact within this time window is memorable or traceable, so we assume that only a fraction g of the secondary contacts within this window are eventually quarantined. Quarantine begins after a fixed delay of Δ2 days after the isolation of the index case, representing the time required for the contact to be identified by contact tracers and to enter quarantine. For those who are quarantined, we assume that they cannot infect further for the remaining duration of their infectious period. This assumption of perfect adherence to quarantined once identified through contact tracing will lead to an overestimation of TTIQ effectiveness. However, any lack of adherence to isolation is easily accounted for in the model by reducing g. Importantly, quarantine occurs independently of whether these secondary infections are asymptomatic or will eventually develop symptoms. Furthermore, contact tracing can also achieved through digital app-based technology [12]. The proposed model applies to both manual and digital contact tracing, but we note that we would expect different parameter combinations for digital versus manual contact tracing, for example reduced delays Δ2 for digital contact tracing [12, 13].

Quarantine shortens the duration in which the identified secondary contacts can transmit further to tertiary contacts (Fig 1B). For each quarantined secondary contact, we calculate the number of onward infections by computing the cumulative fraction of the infection time distribution before quarantine begins and multiplying by Ra or Rs, depending on whether the secondary contact is classified as asymptomatic or symptomatic.

If a secondary contact is not quarantined, then they could be detected after symptom onset (if not asymptomatic) as a new index case and subsequently isolated. The number of onward infections that result from these individuals is typically higher than for those who are quarantined, as they have to wait until symptom onset before they can be isolated, or they may not develop symptoms at all in which case they are not isolated. Finally, some secondary contacts are not quarantined or isolated, and will infect Ra or Rs tertiary contacts. The average number of infections caused by the quarantined, isolated, and non-isolated secondary contacts is then the number of tertiary infections per index case. See S1 Appendix for the full calculation.

TTIQ parameters

The efficacy of the TTIQ interventions depends on how quickly and accurately they are implemented. To this end, we have introduced five parameters to describe the TTIQ process (Table 1). We systematically explore this TTIQ parameter space, first for the testing & isolation intervention in the absence of contact tracing (Fig 1A), and then with additional tracing & quarantine (Fig 1B).

Table 1. Parameter definitions for the TTIQ interventions.

Parameter Description Range
f Probability that a symptomatic individual is isolated from the population 0% ≤ f ≤ 100%
Δ1 Time delay between symptom onset and isolation Δ1 ≥ 0 days
τ Duration prior to symptom onset in which contacts are identifiable τ ≥ 0 days
g Fraction of identifiable contacts that are successfully traced and quarantined per isolated index case 0% ≤ g ≤ 100%
Δ2 Time delay between isolation of the index case and the start of quarantine for the secondary contacts Δ2 ≥ 0 days

The delay and lookback parameters Δ1, Δ2, and τ are illustrated in Fig 1.

Due to the high between-country variability of testing coverage (f), contact tracing success (g), and the respective delays, as well as the lack of publicly-available data on these topics, we keep these values as free parameters in our analyses.

In all analyses we focus on fixed TTIQ parameter values for all individuals in the branching process, as opposed to sampling each individual’s parameters from a distribution. This simplifies the visualisation and interpretation of results. We expect that the averaged results when using distributed parameters would closely reflect our fixed-value results, but would lead to increased variance/uncertainty in our estimates. Heterogeneity in the individuals’ baseline reproductive number (due to contact number and transmission heterogeneities) is addressed in S3 Appendix.

Effective reproduction number

The effectiveness of the TTIQ intervention can be quantified by calculating the effective reproduction number in the presence of the interventions, RTTIQ, which describes the expected number of secondary infections per infected individual. If RTTIQ > 1 then the epidemic is growing, while a value of less than one means the epidemic is being suppressed. For our branching process model, we define the reproductive number as RTTIQ = n3/n2, where n2 and n3 are the expected number of secondary and tertiary infections per index case, respectively. In other words, we define the reproductive number as the average number of infecteds in the third generation per infected in the second generation. It is necessary to work with the third generation (as opposed to just the first and second generations) as this is where the impact of contact tracing and quarantine is first observed. Under strategies of testing & isolation alone (i.e. no contact tracing), we use the notation RTI for clarity.

Computing uncertainties

As shown in Fig I in S1 Appendix, there is considerable uncertainty in the variance of the inferred generation time distribution and infectivity profile. We propagate this uncertainty into our calculation of RTTIQ. Briefly, we sample parameter combinations that make up the 95% confidence interval of the generation time distribution and infectivity profile, and then compute RTTIQ for each parameter set. The maximum and minimum of these values then describe the confidence interval for the level of transmission. Complete details are provided in S1 Appendix.

Interactive app

To complement the results in this manuscript, and to allow readers to investigate different TTIQ parameter settings, we have developed an online interactive application. This can be found at https://ibz-shiny.ethz.ch/covidDashboard/ttiq.

Results

Reducing transmission by testing & isolating symptomatic cases

Based on our transmission model, testing & isolating of symptomatic cases alone (i.e. without additional contact tracing & quarantine) is capable of suppressing epidemic growth (RTI < 1) with a baseline R-value in the absence of TTIQ of up to 1.76 [95% confidence interval (CI): 1.57,1.98], assuming that asymptomatic individuals contribute α = 20% of infections (Fig II in S2 Appendix). To achieve this level of suppression, each symptomatic individual (f = 100%) would have to isolate immediately at symptom onset (Δ1 = 0 days), representing the upper limit of testing & isolation performance. We again note that the baseline R parameter depends on the current suppression measures against SARS-CoV-2 transmission (social distancing, mask wearing, home office, etc., but not TTIQ interventions), as well as seasonality, the variant under consideration, and levels of immunity/vaccination. Importantly, this predicted upper limit of R = 1.76 is below the estimated R0 of SARS-CoV-2 (R0 ≈ 2.5 [9]—5.7 [24]). Hence, testing & isolating of symptomatic cases alone as a control strategy would not have been sufficient to prevent epidemic growth, even before the emergence of more transmissible variants. One would have to reduce the number of susceptible individuals in the population by at least 30% (e.g. through vaccination) for testing & isolating alone to be a viable strategy.

The region of (f, Δ1) parameter space in which RTI is less than one, i.e. the region in which an epidemic can be controlled by testing & isolating, is shrinking for higher R epidemics (Fig 2A). Higher testing & isolation coverage (f) or shortened delays between symptom onset and isolation (Δ1) are required to control SARS-CoV-2 outbreaks as R increases. By increasing the fraction of symptomatic individuals that are isolated (f), there can be a greater delay to isolation without any increase in RTI, but with diminishing returns.

Fig 2. The reproductive number RTI under testing & isolation only.

Fig 2

A: The impact of testing & isolation on RTI as a function of the fraction of symptomatic individuals that are isolated (f; x-axis) and delay to isolation after symptom onset (Δ1; y-axis) for different baseline R values (columns). The black line represents the critical reproductive number RTI = 1. Above this line (orange zone) we have on average more than one secondary infection per infected and the epidemic is growing. Below this line (blue zone) we have less than one secondary infection per infected and the epidemic is suppressed. Dashed lines are the 95% confidence interval for this threshold, representing the uncertainty in the inferred generation time distribution and infectivity profile. B: Lines correspond to slices of panel A at a fixed delay to isolation Δ1 = 0, 2, or 4 days after symptom onset (colour). Shaded regions are 95% confidence intervals for the reproductive number, representing the uncertainty in the inferred generation time distribution and infectivity profile. Horizontal grey line is the threshold for epidemic control (RTI = 1). We fix the fraction of transmission that is attributed to asymptomatic infections to α = 20%, where asymptomatic individuals are not tested or isolated. Data provided in S1 Dataset.

A SARS-CoV-2 outbreak with R = 1.1 (in the absence of TTIQ) can be controlled by isolating as few as 21% [95% confidence interval (CI): 18%,25%] of symptomatic individuals at the time of symptom onset (Δ1 = 0 days) (Fig 2B). If the symptomatic individuals wait Δ1 = 2 days after symptom onset before isolating (i.e. they wait for a test result), then 39% [CI: 30%,54%] of symptomatic infecteds would have to be isolated for the epidemic to be controlled. Isolating after Δ1 = 4 days would be insufficient to control the epidemic even if all symptomatic individuals were isolated [CI: 63%,n.a.]. For faster-spreading SARS-CoV-2 outbreaks or more transmissible variants (baseline R = 1.5 in the absence of TTIQ), we would require 77% [CI: 67%,91%] of symptomatic infecteds to be isolated immediately after they develop symptoms (Δ1 = 0 days) to control the epidemic. With a delay Δ1 ≥ 2 days, testing & isolating of symptomatic cases would be insufficient to control the epidemic, even if 100% of symptomatic infecteds are isolated.

We have predominantly focussed on α = 20% of infections being attributable to persistently-asymptomatic individuals in the absence of TTIQ. As this fraction increases, we observe a linear increase in RTI, i.e. increasing the fraction of transmission that is attributable to asymptomatic infections leads to reduced efficacy of testing & isolating, as fewer cases are identified by testing only symptomatics (Fig IIIA in S2 Appendix). It should be noted that under testing & isolation measures, a larger fraction of onward transmission is attributable to asymptomatic infections when compared to the scenario of no TTIQ (Fig IIIB in S2 Appendix).

Reducing transmission by additional contact tracing & quarantine

With additional contact tracing & quarantine, the theoretical upper limit of TTIQ efficacy is greatly increased compared to testing & isolation alone: under perfect conditions with all contacts quarantined immediately after symptom onset in the index case, TTIQ can suppress epidemics with a baseline R-value in the absence of TTIQ of up to 4.24 [95% CI: 3.10,5.83] (Fig II in S2 Appendix for α = 20%). However, it is unlikely that such a high level of suppression could be achieved in practice due to delays and inaccuracies in the contact tracing process.

Under ideal TTIQ conditions, additional tracing & quarantine can more than double the effectiveness of the intervention compared to testing & isolation alone (Fig II in S2 Appendix). However, under more realistic expectations of inaccuracies and delays in the TTIQ processes, the majority of transmission is prevented by testing & isolation if less than g = 60% of contacts are quarantined (S1 Fig).

We can visualise the additional benefit that contact tracing & quarantine brings to testing & isolation in our model by gradually increasing the fraction of contacts that are quarantined, g. For g = 0, no contacts are traced & quarantined, and hence we return to the testing & isolation strategy (Fig 2). By increasing g, we expand the parameter space in which RTTIQ < 1 (Fig 3), i.e. contact tracing allows an epidemic to be controlled for lower fractions of index cases found (f) and/or longer delays to isolating the index case after they develop symptoms (Δ1). Furthermore, for a given set of testing & isolation parameters f and Δ1, we can control higher R-value epidemics with contact tracing & quarantine that would be otherwise uncontrollable.

Fig 3. The impact of tracing & quarantine on the reproductive number.

Fig 3

The impact of tracing & quarantine on the reproductive number RTTIQ as a function of the fraction of symptomatic individuals that are isolated (f; x-axis) and delay to isolation after symptom onset (Δ1; y-axis), for different contact tracing & quarantine success probabilities g (colour) across different baseline R values (columns). We fix Δ2 = 2 days and τ = 2 days. The contours separate the regions where the epidemic is growing (RTTIQ > 1; top-left) and the epidemic is suppressed (RTTIQ < 1; bottom-right). The contours for g = 0 are equivalent to the contours in Fig 2. We fix the fraction of transmission that is attributed to asymptomatic infections to α = 20%. Asymptomatic individuals are not tested or isolated, but are subject to quarantine after contact tracing. We do not show confidence intervals for clarity of presentation. Data provided in S1 Dataset.

To obtain a systematic understanding of the impact that each parameter of the TTIQ process has on the effective reproductive number RTTIQ, we can individually vary each of the five TTIQ parameters. To this end, we calculate RTTIQ for focal parameter sets of (f, g, Δ1, Δ2, τ). We then perturb each single parameter, keeping the remaining four parameters fixed, and compute the new value of RTTIQ (Fig 4).

Fig 4. The response of the reproductive number RTTIQ to single TTIQ parameter perturbations.

Fig 4

We set the baseline R = 1.5 throughout, which is the intensity of the epidemic in the absence of any TTIQ intervention. We consider four focal TTIQ parameter combinations, with f ∈ {30%, 70%}, Δ1 ∈ {0, 2} days, g = 50%, Δ2 = 1 day, and τ = 2 days. RTTIQ for the focal parameter sets are shown as thin black lines. With f = 0 (no TTIQ) we expect RTTIQ = R (upper grey line). We then vary each TTIQ parameter individually, keeping the remaining four parameters fixed at the focal values. The upper panel shows the probability parameters f and g, while the lower panel shows the parameters which carry units of time (days). The critical threshold for controlling an epidemic is RTTIQ = 1 (lower grey line). We fix the fraction of transmission that is attributed to asymptomatic infections to α = 20%. A sensitivity analysis to α is shown in Fig I in S2 Appendix. Asymptomatic individuals are not tested or isolated, but are subject to quarantine after contact tracing. Data provided in S1 Dataset.

Modifying the fraction of symptomatic index cases that are identified and isolated (f) has the largest effect of all parameter changes. By identifying more index cases (increasing f), we not only prevent the onward transmission to secondary contacts through isolation, but we also allow infected contacts to be traced and quarantined.

Increasing the fraction of secondary contacts that are quarantined (g) has a smaller benefit than increasing f. If only 30% of symptomatic index cases are identified, then increasing g results in a small reduction of RTTIQ and for R = 1.5 the epidemic cannot be controlled even if all secondary contacts (g = 100%) of known index cases are quarantined (Fig 4A & 4B). However, if a large fraction of symptomatic index cases are identified (f = 70%), then increasing g can control an epidemic that would be out of control in the absence of contact tracing (Fig 4C & 4D).

After increasing f, the next most effective control strategy is to reduce the delay between symptom onset and isolation of the index case (Δ1). Reducing the time taken to quarantine secondary contacts (Δ2) has a lesser effect on RTTIQ. Finally, looking back further while contact tracing (increasing τ) allows more secondary contacts to be traced and quarantined. However, this does not translate into a substantial reduction in RTTIQ as the extra contacts which are traced have already been infectious for a long time, and will thus have less remaining infectivity potential to be prevented by quarantine. Hence increasing τ comes with diminishing returns.

To check the robustness of these effects across all parameter combinations (not just perturbing a single parameter), we randomly sampled parameter combinations (f, g, Δ1, Δ2, τ) and used linear discriminant analysis (LDA) to capture the impact that each parameter has on RTTIQ (Fig 5). We find that f is the dominant parameter to determine the reproductive number, followed by Δ1, g, Δ2, and finally τ has the smallest impact. Furthermore, by looking at the distribution of the randomly-sampled TTIQ parameters across different RTTIQ values (S2 Fig), we observe that low f values are strongly associated with low TTIQ effectiveness (although a high f value is not necessarily associated with high effectiveness).

Fig 5. Linear discriminant analysis (LDA) of the impact of TTIQ strategies on the reproductive number RTTIQ.

Fig 5

We fix the baseline R = 1.5 and α = 20%, and then we randomly uniformly sample 10,000 parameter combinations from f ∈ [0%, 100%], g ∈ [0%, 100%], Δ1 ∈ [0, 5] days, Δ2 ∈ [0, 5] days, and τ ∈ [0, 5] days. The reproductive number is calculated for each TTIQ parameter combination, and the output (RTTIQ) is categorised into bins of width 0.1 (colour). We then use LDA to construct a linear combination (LD1) of the five (normalised) TTIQ parameters which maximally separates the output categories. We then predict the LD1 values for each parameter combination, and construct a histogram of these values for each category. The lower panel shows the components of the primary linear discriminant vector (LD1). By multiplying the (normalised) TTIQ parameters by the corresponding vector component, we arrive at the LD1 prediction which corresponds to the predicted reproductive number under that TTIQ strategy. Longer arrows (larger magnitude components) correspond to a parameter having a larger effect on the reproductive number. The distributions of parameters per categorised reproductive number is shown in S2 Fig. Data provided in S1 Dataset.

The output of the LDA analysis is dependent on the range of parameter values from which we sample (S3 Fig). While f and g are naturally bounded from 0% to 100%, the time-valued parameters Δ1, Δ2, and τ have no natural upper limit. Without empirical data to inform these prior distributions, we focus on durations from zero to five days as shown in Fig 4. Furthermore, as a linear approximation the LDA does not capture the effect of covariance between parameters. To capture these parameter interactions, we can also include quadratic terms (e.g. f × g) as independent parameters in the LDA. From this analysis (S4 Fig), we see that the terms f × Δ1 and g × Δ2 correlate positively with RTTIQ, such that increasing the delays Δ1 and Δ2 can negate the increase in TTIQ efficacy that is bought by increasing f or g, respectively.

Finally, we comment on the role of asymptomatic transmission across the TTIQ intervention. Although quarantine of a traced contact occurs independently of whether that contact will be symptomatic or asymptomatic, the probability that the contact is identified in the first place depends on whether the infector is asymptomatic or not. Hence, TTIQ will decrease in effectiveness as the fraction of transmission that is attributable to asymptomatic individuals (α) increases (Fig IIA in S2 Appendix).

Discussion

By combining empirically well-supported estimates of the infection timing of SARS-CoV-2 with a simple model of transmission dynamics, we have calculated the impact of test-trace-isolate-quarantine (TTIQ) interventions against the spread of COVID-19. Under idealised conditions, testing & isolation plus contact tracing & quarantine can prevent substantially more transmission than testing & isolation only. However, the effects of delays and inaccuracies in the TTIQ processes are compounded for contact tracing & quarantine, which ultimately relies on index case identification to be effective. Ignoring this compounding effect would potentially overestimate the impact that contact tracing can have on transmission reduction. Based on our systematic analysis, we find that the greatest improvement to the TTIQ process would come from increased identification and isolation of symptomatic index cases and reduction of delay between symptom onset and isolation. These parameters contribute to the direct reduction of onward infection from an index case, and optimising them allows more contacts to be traced earlier. These results align with those of Grantz et al. [17]. From a public health perspective, increasing the identification and speeding up the isolation of symptomatic index cases could be achieved through widely-available rapid testing. Despite the potentially lower sensitivity of rapid tests compared to RT-PCR tests, their effectiveness at reducing transmission has been demonstrated in simulation studies of index case isolation [25].

Increasing the duration of the contact tracing window by looking back further in time has limited return under our model of forward contact tracing (identifying who was infected by the index case). However, if we were interested in identifying the source of infection (backwards contact tracing), then increasing the duration of the contact tracing window could lead to the identification of transmission clusters.

When comparing to the findings of Ferretti et al. [12], we find that contact tracing has less impact on epidemic suppression, and that the speed of contact tracing is of secondary importance to the speed of isolating index cases. This difference can be attributed to Ferretti et al.’s [12] use of Fraser et al.’s [26] approach to model contact tracing and isolation as independent events (i.e. tracing an index cases’ contacts says nothing about whether the index case has been isolated). Although this assumption leads to analytically tractable predictions of the reproductive number under TTIQ, it also leads to an overestimation of contact tracing’s impact [26]. Our approach can therefore be considered as a methodological advance over Fraser et al. [26] and should be employed in the analysis of future epidemic scenarios.

Kretzschmar et al. [13]—this time with contact tracing dependent on testing & isolation—concluded that reducing the delay to isolation after symptom onset has the greatest impact on TTIQ effectiveness. They further showed that the effective reproductive number was insensitive to varying the testing coverage, although only at a fixed delay of four days between symptom onset and index case isolation. Based on our systematic LDA analysis with quadratic parameters (S4 Fig), we know that there is considerable interaction between testing coverage f and isolation delay Δ1. Therefore, we expect that sensitivity to testing coverage would appear at shorter delay values, and on average across these parameters we show that increasing f has a greater effect on the reproductive number than decreasing Δ1.

Our approach and results are crucially dependent on the distribution of infection times (generation time and infectivity profile) and although we have used well-supported estimates, there are inherent limitations to deriving these distributions based on transmission pairs. These transmission pairs are representative of symptomatic cases, but the infectiousness profiles for persistently-asymptomatic infections are as-yet unknown [6]. We have assumed that asymptomatically-infected individuals have the same infection timing distributions as symptomatic individuals, but any differences between the shapes of these profiles will lead to different results in terms of transmission reduction. Uncertainty in the inferred infection timing distributions is carried through our analysis and is captured by the confidence intervals shown in the figures and reported in the text. Furthermore, we do account for potential differences in the overall transmissibility between asymptomatic and symptomatic individuals. It is possible that the 20% of infections that are asymptomatic are responsible for less than 20% of transmission in the absence of any TTIQ interventions. We show in S2 Appendix that TTIQ becomes more effective as asymptomatic transmission decreases. Therefore, our results could be underestimating TTIQ efficacy, to a small extent.

Our model is parametrised on distributions of the timing of transmission estimated prior to the emergence of new, more transmissible variants. If new variants simply have higher transmissibility—without changes in the timing of transmission—our fundamental analysis remains the same. In this case, TTIQ may be insufficient to control the spread of highly-transmissible (higher R-value) new variants, as captured in Figs 2 and 3. If the increased transmission of the new variants is due to a longer-lasting infectious period, then we expect TTIQ to be more efficient, as the additional transmission events would be prevented by isolation and quarantine. If the new variants are more transmissible during early (presymptomatic) infection, then we expect the relative benefit of contact tracing over testing & isolating to increase.

In terms of modelling the TTIQ process, we have assumed that identified symptomatic index cases are isolated after symptom onset and have their contacts traced. If the index case fails to adhere to the isolation protocol, then we will overestimate the amount of transmission prevented by isolation. However, uncertainty in whether contacts adhere to quarantine protocols, or whether contact tracers actually identify contacts, is captured in the parameter g. Lower adherence to quarantine or missed contacts due to overwhelmed contact tracers is captured by lowering g. Hill et al. [27] recently demonstrated in a network modelling study that increased adherence to isolation and contact tracing measures can significantly reduce the size of an outbreak.

In our approach, we assume a baseline R that is defined in the absence of the modelled TTIQ intervention (i.e. no testing, isolation, or contact tracing). The empirical value for this baseline R is not known, as observed values of the reproductive number in most countries include the impact of the modelled intervention. In itself, this does not impact the result of our analysis: the impact of isolation remains higher than that of quarantine across different values of R (Fig 3). However, in contexts where a large proportion of symptomatic individuals already isolate, the scope for increasing isolation may be limited. Under such circumstances, mass or random testing, if successfully followed by isolation, may be a promising intervention. This is supported by data on the effectiveness of mass testing interventions, for example in Slovakia [28]. In this scenario it would be possible to identify asymptomatic index cases, as well as identifying eventually-symptomatic cases before symptom onset. Through this increased index case identification and isolation, as well as the reduced time that these index cases are infectious and non-isolated, and also reducing the number of secondary contacts that have to be identified by contact tracing, mass/random testing would therefore increase the overall performance of TTIQ.

Our analysis is, to some extent, limited by the assumptions which underlie the branching process framework. The infinite population size assumption prevents us from computing the fraction of population that is infected, or from a socioeconomic point of view the fraction of population isolated/quarantined at a given time. Furthermore, with the branching process we cannot observe long-term effects caused by depleting susceptibles through quarantine, immunity, or death. However, the branching process approach is valid over short time scales (like the two generations of transmission that we calculate), provided that the susceptible population size is much larger than R2. The effect of susceptible depletion can also be incorporated by lowering the baseline reproductive value R in the model.

Assuming a fixed value of the baseline reproductive value R is a further limitation of our approach, as the impact of overdispersion of contact number distributions and superspreading is well documented for infectious disease dynamics [29]. If we were to sample R for the index case and each secondary case from identical overdispersed negative binomial distributions, then the expectation value would be unchanged from our current approach: only the variance/uncertainty in our predictions would increase (S3 Appendix). The equivalence of expectation values could break down if we were to assume a finite capacity of contact tracing, such that the quarantined fraction of contacts of index cases with a large individual reproductive number may be less than g.

Conclusion

Here we have shown through systematic analysis how the TTIQ processes can be optimised to bring the effective reproductive number below one. Crucially, contact tracing & quarantine adds security to testing & isolating strategies, where high coverage and short delays are necessary to control an epidemic. By improving the testing & isolation coverage and reducing the delay to index case isolation, we can greatly increase the efficacy of the overall TTIQ strategy.

Supporting information

S1 Appendix. Supplementary materials and methods.

This file contains mathematical details of the model and analysis.

(PDF)

S2 Appendix. Supplementary results I.

Impact of asymptomatics.

(PDF)

S3 Appendix. Supplementary results II.

Overdispersion.

(PDF)

S1 Fig. Quarantine versus isolation.

The fraction of prevented transmission that can be attributed to quarantine, rather than isolation. Let RTTIQ(g) be the reproductive number in the presence of TTIQ interventions in which a fraction g of contacts of identified index cases are quarantined. In the absence of TTIQ measures, we expect a reproductive number of R. We then define Y(g) = RRTTIQ(g) as reduction of transmission due to TTIQ, and Y(0) = RRTTIQ(0) as the reduction of transmission due only to isolation (i.e. no contact tracing & quarantine). We then define the fraction of prevented transmission due to quarantine as [Y(g) − Y(0)]/Y(g), which we plot as a function of g. Note that we are computing how much extra transmission is prevented by quarantine, which may just be one days worth of transmission before the contact becomes symptomatic and would anyway be isolated. We vary the fraction of symptomatic index cases that are isolated f (colour), and we fix Δ1 = Δ2 = τ = 2 days. We further fix the fraction of transmission that is attributed to asymptomatic infections to α = 20% and R = 1.5 (although the fraction shown is independent of R). Above the horizontal line, more transmission is prevented by quarantine than by isolation. Data provided in S1 Dataset.

(PDF)

S2 Fig. LDA parameter distributions.

The distributions of (normalised) parameters per categorised group of RTTIQ as used in the LDA analysis in Fig 5 in the manuscript. We uniformly sample 10,000 parameter combinations from f ∈ [0%, 100%], g ∈ [0%, 100%], Δ1 ∈ [0, 5] days, Δ2 ∈ [0, 5] days, and τ ∈ [0, 5] days. The reproductive number RTTIQ is calculated for each parameter combination and categorised into bins of width 0.1 (colour). The upper row shows how many parameter combinations resulted in each category of RTTIQ. The next five rows show how the parameters are distributed within each category, while the horizontal bar shows the median parameter value. We fix R = 1.5 and α = 20%. Data provided in S1 Dataset.

(PDF)

S3 Fig. LDA range sensitivity.

Impact of varying the range from which we sample time-dependent parameters on the LDA output (without quadratic terms). Each bar represents the magnitude of the components of the primary linear discriminant vector (LD1) for each parameter (colour). Data provided in S1 Dataset.

(PDF)

S4 Fig. LDA with quadratic terms.

Linear discriminant analysis (LDA) of the impact of TTIQ strategies on the reproductive number RTTIQ, now including quadratic terms. We use the same uniformly-sampled data as in Fig 5 in the manuscript, but now we include the quadratic parameter terms (e.g. f × g) as discriminators too. We take the square root of these quadratic terms to ensure the parameter distributions are not overly skewed. We then use LDA to construct a linear combination (LD1) of the now 15 TTIQ parameters which maximally separates the output categories. We then predict the LD1 values for each parameter combination, and construct a histogram of these values for each category. The lower panel shows the components of the primary linear discriminant vector (LD1). By multiplying the (normalised) TTIQ parameters by the corresponding vector component, we arrive at the LD1 prediction which corresponds to the predicted reproductive number under that TTIQ strategy. Longer arrows (larger magnitude components) correspond to a parameter having a larger effect on the reproductive number. Data provided in S1 Dataset.

(PDF)

S1 Dataset. Raw data for quantitative figures.

(ZIP)

Data Availability

All code and data are publicly available on GitHub (http://github.com/ashcroftp/COVID-TTIQ).

Funding Statement

This study was funded by the Swiss National Science Foundation (grant no. 310030B_176401, awarded to SB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.WHO. Contact Tracing in the Context of COVID-19. 2020;WHO/2019-nCoV/Contact_Tracing/2020.1.
  • 2. Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID-19 Epidemic in Switzerland: On the Importance of Testing, Contact Tracing and Isolation. Swiss Medical Weekly. 2020;150 (1112). [DOI] [PubMed] [Google Scholar]
  • 3. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al. Effectiveness of Isolation, Testing, Contact Tracing, and Physical Distancing on Reducing Transmission of SARS-CoV-2 in Different Settings: A Mathematical Modelling Study. The Lancet Infectious Diseases. 2020;20(10):1151–1160. doi: 10.1016/S1473-3099(20)30457-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal Dynamics in Viral Shedding and Transmissibility of COVID-19. Nature Medicine. 2020;26(5):672–675. doi: 10.1038/s41591-020-0869-5 [DOI] [PubMed] [Google Scholar]
  • 5. Ashcroft P, Huisman JS, Lehtinen S, Bouman JA, Althaus CL, Regoes RR, et al. COVID-19 Infectivity Profile Correction. Swiss Medical Weekly. 2020;150:w20336. [DOI] [PubMed] [Google Scholar]
  • 6. Ferretti L, Ledda A, Wymant C, Zhao L, Ledda V, Dorner LA, et al. The Timing of COVID-19 Transmission. medRxiv. 2020; p. 2020.09.04.20188516. doi: 10.1101/2020.09.04.20188516 [DOI] [Google Scholar]
  • 7. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and Transmission Potential of Asymptomatic and Presymptomatic SARS-CoV-2 Infections: A Living Systematic Review and Meta-Analysis. PLOS Medicine. 2020;17(9):e1003346. doi: 10.1371/journal.pmed.1003346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The Implications of Silent Transmission for the Control of COVID-19 Outbreaks. Proceedings of the National Academy of Sciences. 2020;117(30):17513–17515. doi: 10.1073/pnas.2008373117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Riou J, Althaus CL. Pattern of Early Human-to-Human Transmission of Wuhan 2019 Novel Coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25(4):2000058. doi: 10.2807/1560-7917.ES.2020.25.4.2000058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Endo A, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Abbott S, Kucharski AJ, Funk S. Estimating the Overdispersion in COVID-19 Transmission Using Outbreak Sizes Outside China. Wellcome Open Research. 2020;5:67. doi: 10.12688/wellcomeopenres.15842.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Adam DC, Wu P, Wong JY, Lau EHY, Tsang TK, Cauchemez S, et al. Clustering and Superspreading Potential of SARS-CoV-2 Infections in Hong Kong. Nature Medicine. 2020;26:1714–1719. doi: 10.1038/s41591-020-1092-0 [DOI] [PubMed] [Google Scholar]
  • 12. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 Transmission Suggests Epidemic Control with Digital Contact Tracing. Science. 2020;368 (6491). doi: 10.1126/science.abb6936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM, Bonten MJM. Impact of Delays on Effectiveness of Contact Tracing Strategies for COVID-19: A Modelling Study. The Lancet Public Health. 2020;5(8):e452–e459. doi: 10.1016/S2468-2667(20)30157-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Contreras S, Dehning J, Loidolt M, Zierenberg J, Spitzner FP, Urrea-Quintero JH, et al. The Challenges of Containing SARS-CoV-2 via Test-Trace-and-Isolate. Nature Communications. 2021;12(1):378. doi: 10.1038/s41467-020-20699-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Quilty BJ, Clifford S, Hellewell J, Russell TW, Kucharski AJ, Flasche S, et al. Quarantine and Testing Strategies in Contact Tracing for SARS-CoV-2: A Modelling Study. The Lancet Public Health. 2021;6(3):E175–E183. doi: 10.1016/S2468-2667(20)30308-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Ashcroft P, Lehtinen S, Angst DC, Low N, Bonhoeffer S. Quantifying the Impact of Quarantine Duration on COVID-19 Transmission. eLife. 2021;10:e63704. doi: 10.7554/eLife.63704 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Grantz KH, Lee EC, McGowan LD, Lee KH, Metcalf CJE, Gurley ES, et al. Maximizing and Evaluating the Impact of Test-Trace-Isolate Programs: A Modeling Study. PLOS Medicine. 2021;18(4):e1003585. doi: 10.1371/journal.pmed.1003585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and Non-Pharmaceutical Interventions for COVID-19: A Mathematical Modelling Study. The Lancet Infectious Diseases. 2021;21(6):793–802. doi: 10.1016/S1473-3099(21)00143-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Sonabend R, Whittles LK, Imai N, Perez-Guzman PN, Knock ES, Rawson T, et al. Non-Pharmaceutical Interventions, Vaccination, and the SARS-CoV-2 Delta Variant in England: A Mathematical Modelling Study. The Lancet. 2021;398(10313):1825–1835. doi: 10.1016/S0140-6736(21)02276-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Lehtinen S, Ashcroft P, Bonhoeffer S. On the Relationship between Serial Interval, Infectiousness Profile and Generation Time. J R Soc Interface. 2021;18(174):20200756. doi: 10.1098/rsif.2020.0756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated Transmissibility and Impact of SARS-CoV-2 Lineage B.1.1.7 in England. Science. 2021;372 (6538). doi: 10.1126/science.abg3055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Althaus CL, Baggio S, Reichmuth ML, Hodcroft EB, Riou J, Neher RA, et al. A Tale of Two Variants: Spread of SARS-CoV-2 Variants Alpha in Geneva, Switzerland, and Beta in South Africa. medRxiv. 2021; p. 2021.06.10.21258468. doi: 10.1101/2021.06.10.21258468 [DOI] [Google Scholar]
  • 23. Alizon S, Haim-Boukobza S, Foulongne V, Verdurme L, Trombert-Paolantoni S, Lecorche E, et al. Rapid Spread of the SARS-CoV-2 δ Variant in the Area of Paris (France) in June 2021. medRxiv. 2021; p. 2021.06.16.21259052. doi: 10.1101/2021.06.16.21259052 [DOI] [Google Scholar]
  • 24. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infectious Diseases. 2020;26(7):1470–1477. doi: 10.3201/eid2607.200282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test Sensitivity Is Secondary to Frequency and Turnaround Time for COVID-19 Screening. Science Advances. 2021;7(1):eabd5393. doi: 10.1126/sciadv.abd5393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors That Make an Infectious Disease Outbreak Controllable. Proceedings of the National Academy of Sciences. 2004;101(16):6146–6151. doi: 10.1073/pnas.0307506101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Hill EM, Atkins BD, Keeling MJ, Dyson L, Tildesley MJ. A Network Modelling Approach to Assess Non-Pharmaceutical Disease Controls in a Worker Population: An Application to SARS-CoV-2. PLOS Computational Biology. 2021;17(6):e1009058. doi: 10.1371/journal.pcbi.1009058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M, working Group5 CC, et al. The Impact of Population-Wide Rapid Antigen Testing on SARS-CoV-2 Prevalence in Slovakia. Science. 2021;372(6542):635–641. doi: 10.1126/science.abf9648 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the Effect of Individual Variation on Disease Emergence. Nature. 2005;438(7066):355–359. doi: 10.1038/nature04153 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Seth Blumberg

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

5 Oct 2021

PONE-D-21-26262Test-trace-isolate-quarantine (TTIQ) intervention strategies after symptomatic COVID-19 case identificationPLOS ONE

Dear Dr. Ashcroft,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Additional Editor Comments:

I found this manuscript to be thoughtfully and clearly written. I think the definition of R = R_3/R_2 is a novel and useful metric for evaluating TTIQ. I also like the interactive graphic. Meanwhile, please address all comments made by the reviewers. Reviewer 1's insightful comments should help to enrich the paper. However per PLOS One's publication criteria it is not necessary to pursue additional analyses - provided the model is clearly articulated and limitations are identified. In addition, I like Reviewer 2's suggestion to make code available and to include a paragraph that relates the methodological results to specific public health interventions. Please note that Reviewer 2's listed references on transmission heterogeneity do not need to be included.

Please submit your revised manuscript by Nov 19 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Seth Blumberg

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This study was funded by the Swiss National Science Foundation (grant no. 310030B_-176401)."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"This study was funded by the Swiss National Science Foundation (grant no. 310030B_176401, awarded to SB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: ### Summary

In their manuscript, Ashcroft and coauthors propose a branching process model to assess the effectiveness of test-trace-isolate-quarantine TTIQ interventions on the containment of COVID-19. Their findings are overall consistent with the large body of evidence showing that TTI may help curb the spread of infectious diseases --- if done properly [1--6]. However, while the authors incorporate great detail into the transmission of COVID-19 by using empirical distributions for the generation/serial intervals and the time from contagion to symptoms onset, imperfections of the TTIQ interventions and all connection with its real-life implementation and its challenges are overseen (e.g., imperfect isolation, limited contact tracing capacity, the cost-effectiveness of quarantining large fractions of the population [2--4,6]).

Below find some observations for improvement.

## Major

1. Currently, there is no category for recovered/vaccinated individuals --- how does epidemic spread affect the baseline reproduction number? How do the authors compute current COVID-19 incidence?

2. What kind of contact tracing is here considered? If manual, there should be a maximum incidence from which no more contacts could be treated or only primary contacts would be prioritized (e.g., $\\tau\\to 0$ in the notation used in the manuscript) [3,4]. If digital contact tracing was used, how is the threshold defined? What's the cost of quarantine and the fraction of the population currently isolated? see, e.g., [6]

3. The definition of _symptoms_ is ambiguous; do the authors refer to COVID-specific symptoms, like loss of smell/taste or other less common symptoms? [7] This could affect the value of $a$ and $\\alpha$. How do symptoms-specificity relate to testing criteria in the event of high COVID-19 incidence?

4. How does the baseline reproduction number relate to the data-driven, testing-dependent observed reproduction number? how does the latter relate to $R_0$, $R_{\\text{TTIQ}}$, and $R_{\\rm TI}$? All reproduction numbers should share the tipping point at $R=1$, but their absolute value depends on the assumptions of the generation interval.

5. Despite being conceptually different, isolation and quarantine are implemented in the same way in the model (i.e., individuals are removed from the infectious pool and do not contribute further to spread). Isolation/Quarantine is deemed imperfect, as individuals share households, choose not to comply with the instructions, or hide their diagnosis because of economic pressure. The above would lead to identified (suspected) and unidentified new infections, contributing further to the spread.

6. What are the testing rates and absolute values behind $f$ and $g$? for $f$, the sensitivity of self-administrated tests is considerably lower than point-of-care administrated tests [8], and thus higher rates of false negatives would arise. On the other hand, point-of-care tests are limited, and individuals showing symptoms are told not to go there, thus also favoring underreporting. For a given value of $f$, how many tests per million per day have to be administrated? And for a given value of $g$ and an average number of close contacts per index case, how many calls have to be performed by the tracing agencies before finding a $g$ % of the newly generated cases? Is it reasonable to assume that all of them would be found exactly $\\Delta_2$ days after the report? How does the model deal with individuals that are simultaneously identified as close contact and index case?

7. I wonder whether it is correct to compare the efficacy of testing-isolating and tracing-quarantining in absolute terms. As I understand it, contact tracing cannot happen without testing; thus, it is conditional to it.

8. There is something odd with Figure S6; I would have expected the trends to be the other way around (if analyzed conditional one to each other). Currently, it seems that to improve the efficacy of contact tracing, we would have to miss more cases in the testing stage.

## Minor

1. Abstract and throughout the manuscript: currently, it reads "SARS-CoV-2 pandemic", but it should be "COVID-19 pandemic", as the latter refers to the disease.

2. There are parts in the introduction that would better fit (and are redundant with) the discussions section.

3. Lines 126--128: missing reference?

4. Figures in general: perhaps larger tick labels and larger fonts for figure legends

5. Discussion: (e.g., lines 418--422) Sensitivity analysis is typically included in the supplementary materials, as in the study of Kretzschmar and coauthors [9].

6. A sensitivity analysis for the asymptomatic fraction should also be performed (as it depends on testing criteria and it's likely to impact the effectiveness of testing policies)

7. How would random testing be implemented in this framework?

8. Currently, delays are modeled as a fixed parameter. However, how late an individual receives a positive test result is a random variable likely to be overdispersed (and the same for contact tracing). Can the authors perhaps discuss how this would affect their results?

## References

[1] Kerr, C. C., Mistry, D., Stuart, R. M., Rosenfeld, K., Hart, G. R., Núñez, R. C., ... & Klein, D. J. (2021). Controlling COVID-19 via test-trace-quarantine. Nature communications, 12(1), 1-12.

[2] Kretzschmar, M. E., Rozhnova, G., & van Boven, M. (2021). Isolation and contact tracing can tip the scale to containment of COVID-19 in populations with social distancing. Frontiers in Physics, 8, 677.

[3] Contreras, S., Dehning, J., Loidolt, M., Zierenberg, J., Spitzner, F. P., Urrea-Quintero, J. H., ... & Priesemann, V. (2021). The challenges of containing SARS-CoV-2 via test-trace-and-isolate. Nature communications, 12(1), 1-13.

[4] Contreras, S., Dehning, J., Mohr, S. B., Bauer, S., Spitzner, F. P., & Priesemann, V. (2020). Low case numbers enable long-term stable pandemic control without lockdowns. arXiv preprint arXiv:2011.11413.

[5] Gardner, B. J., & Kilpatrick, A. M. (2021). Contact tracing efficiency, transmission heterogeneity, and accelerating COVID-19 epidemics. PLOS Computational Biology, 17(6), e1009122.

[6] Lunz, D., Batt, G., & Ruess, J. (2021). To quarantine, or not to quarantine: A theoretical framework for disease control via contact tracing. Epidemics, 34, 100428.

[7] Nasserie, T., Hittle, M., & Goodman, S. N. (2021). Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA network open, 4(5), e2111417-e2111417.

[8] Lindner, A. K., Nikolai, O., Kausch, F., Wintel, M., Hommes, F., Gertler, M., ... & Denkinger, C. M. (2021). Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 57(4).

[9] Kretzschmar, Mirjam E., et al. "Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study." The Lancet Public Health 5.8 (2020): e452-e459.

Reviewer #2: Summary:

The authors present a well-written and devised study investigating the effect of test-trace-isolate-quarantine (TTIQ) strategies on SARS-CoV2 transmission. Empirical distributions of the generation time, infectivity profile, and incubation period are incorporated into a branching process model with parameters affecting reductions in the distribution of infectivity through time. Early isolation of index cases is found to be the most effective TTIQ strategy and the authors communicate uncertainty in the results exceptionally well throughout. There are a number of typos and a couple aspects of the methods that are a bit unclear. In addition, further discussion or incorporation of the effects of individual heterogeneities in R should be incorporated. Finally, making the code accessible in addition to the app would be helpful for transparency/reproducibility and future derivative work.

Minor Comments & Suggestions:

• Line 39: Introduce TTIQ acronym first time appearing in summary

• Line 64: “were” rather than “are”

• Line 79: “Testing and quarantine do not…” rather than “Testing and tracing does not…”

• Line 124: Might be worth explaining how this is a methodological advance over Fraser et al (2004) by calling attention to a few specific details

• Line 145: Seems like the definition of the infectivity profile should include reference to symptomatic vs asymptomatic infection and clarify how it is defined in the case of an asymptomatic infection. Looks like it’s mentioned in the discussion, but probably worth stating in the methods

• Figure 1 is quite nice, but it’s a bit unclear what the y-axis is meant to represent. Is it the probability of generating a new case at time t? Such that infecteds are more likely to generate new cases around the time of their symptom onset? This makes sense, even as it’s not explicitly incorporated into the distributions used to generate Fig 1, but it’s worth a bit more explicit discussion. Also, in the event that the y axis does represent this transmission probability, it might be worth incorporating this into the timing of secondary cases in the figure such that more of the secondary cases are generated around the time of highest infectiousness, but this is just a minor suggestion that might not be worth the effort to re-configure the figure.

• Code and details such as coding language and additional software packages used should be made available in addition to the app

• Figure 2A: consider using color-blind friendly color palate

• Not sure if possible as I’m not familiar with LDA, but would be very interesting to perform the same analysis on pairs of parameters, i.e. could answer: f is most impactful, but what is the most impactful parameter that interacts with f?

• Line 394: “than” rather than “that”

• Line 452: “contacts” rather than “contracts”

• Might be worth adding a paragraph in the discussion suggesting ways to enact the most impactful TTIQ interventions. This would help translate the results into actionable policy for public health practitioners that may not fully understand the methods and approach. Widely available rapid testing for instance could be suggested as a way to increase f.

o Larremore, D. B., Wilder, B., Lester, E., Shehata, S., Burke, J. M., Hay, J. A., ... & Parker, R. (2021). Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Science advances, 7(1), eabd5393.

Major comments:

• Given the theoretical foundation in branching process theory, it’s worth investigating the implications of the variance of R on the results in addition to its mean. Previous theoretical work on superspreading and the influence of the dispersion parameter assuming R is negative binomially distributed have found it’s important. Especially given the impact of f (fraction of index cases identified), this could lead to interesting insights. If nothing else, I think it’s worth a paragraph in the discussion, as my intuition is that it would affect the variance/confidence intervals of the results and not so much the mean.

o Blumberg, S., & Lloyd-Smith, J. O. (2013). Comparing methods for estimating R0 from the size distribution of subcritical transmission chains. Epidemics, 5(3), 131-145.

o Blumberg, S., & Lloyd-Smith, J. O. (2013). Inference of R 0 and transmission heterogeneity from the size distribution of stuttering chains. PLoS computational biology, 9(5), e1002993.

o Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E., & Getz, W. M. (2005). Superspreading and the effect of individual variation on disease emergence. Nature, 438(7066), 355-359.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Seth Blumberg

24 Jan 2022

Test-trace-isolate-quarantine (TTIQ) intervention strategies after symptomatic COVID-19 case identification

PONE-D-21-26262R1

Dear Dr. Ashcroft,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Seth Blumberg

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for your diligent attention the reviewer comments. I am impressed with this careful, thorough and interesting research.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I thank the authors for the careful consideration of my comments and suggestions. In my opinion, the revised version constitutes a solid contribution to the state-of-the-art, and I congratulate the authors on the fruit of their research.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Seth Blumberg

3 Feb 2022

PONE-D-21-26262R1

Test-trace-isolate-quarantine (TTIQ) intervention strategies after symptomatic COVID-19 case identification

Dear Dr. Ashcroft:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Seth Blumberg

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Supplementary materials and methods.

    This file contains mathematical details of the model and analysis.

    (PDF)

    S2 Appendix. Supplementary results I.

    Impact of asymptomatics.

    (PDF)

    S3 Appendix. Supplementary results II.

    Overdispersion.

    (PDF)

    S1 Fig. Quarantine versus isolation.

    The fraction of prevented transmission that can be attributed to quarantine, rather than isolation. Let RTTIQ(g) be the reproductive number in the presence of TTIQ interventions in which a fraction g of contacts of identified index cases are quarantined. In the absence of TTIQ measures, we expect a reproductive number of R. We then define Y(g) = RRTTIQ(g) as reduction of transmission due to TTIQ, and Y(0) = RRTTIQ(0) as the reduction of transmission due only to isolation (i.e. no contact tracing & quarantine). We then define the fraction of prevented transmission due to quarantine as [Y(g) − Y(0)]/Y(g), which we plot as a function of g. Note that we are computing how much extra transmission is prevented by quarantine, which may just be one days worth of transmission before the contact becomes symptomatic and would anyway be isolated. We vary the fraction of symptomatic index cases that are isolated f (colour), and we fix Δ1 = Δ2 = τ = 2 days. We further fix the fraction of transmission that is attributed to asymptomatic infections to α = 20% and R = 1.5 (although the fraction shown is independent of R). Above the horizontal line, more transmission is prevented by quarantine than by isolation. Data provided in S1 Dataset.

    (PDF)

    S2 Fig. LDA parameter distributions.

    The distributions of (normalised) parameters per categorised group of RTTIQ as used in the LDA analysis in Fig 5 in the manuscript. We uniformly sample 10,000 parameter combinations from f ∈ [0%, 100%], g ∈ [0%, 100%], Δ1 ∈ [0, 5] days, Δ2 ∈ [0, 5] days, and τ ∈ [0, 5] days. The reproductive number RTTIQ is calculated for each parameter combination and categorised into bins of width 0.1 (colour). The upper row shows how many parameter combinations resulted in each category of RTTIQ. The next five rows show how the parameters are distributed within each category, while the horizontal bar shows the median parameter value. We fix R = 1.5 and α = 20%. Data provided in S1 Dataset.

    (PDF)

    S3 Fig. LDA range sensitivity.

    Impact of varying the range from which we sample time-dependent parameters on the LDA output (without quadratic terms). Each bar represents the magnitude of the components of the primary linear discriminant vector (LD1) for each parameter (colour). Data provided in S1 Dataset.

    (PDF)

    S4 Fig. LDA with quadratic terms.

    Linear discriminant analysis (LDA) of the impact of TTIQ strategies on the reproductive number RTTIQ, now including quadratic terms. We use the same uniformly-sampled data as in Fig 5 in the manuscript, but now we include the quadratic parameter terms (e.g. f × g) as discriminators too. We take the square root of these quadratic terms to ensure the parameter distributions are not overly skewed. We then use LDA to construct a linear combination (LD1) of the now 15 TTIQ parameters which maximally separates the output categories. We then predict the LD1 values for each parameter combination, and construct a histogram of these values for each category. The lower panel shows the components of the primary linear discriminant vector (LD1). By multiplying the (normalised) TTIQ parameters by the corresponding vector component, we arrive at the LD1 prediction which corresponds to the predicted reproductive number under that TTIQ strategy. Longer arrows (larger magnitude components) correspond to a parameter having a larger effect on the reproductive number. Data provided in S1 Dataset.

    (PDF)

    S1 Dataset. Raw data for quantitative figures.

    (ZIP)

    Attachment

    Submitted filename: response-PLoSONE.pdf

    Data Availability Statement

    All code and data are publicly available on GitHub (http://github.com/ashcroftp/COVID-TTIQ).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES